Immatics' vaccine prolongs survival in renal cell cancer
This article was originally published in Scrip
Immatics' lead cancer vaccine IMA901 can prolong survival times in renal cell carcinoma patients whose immune system responds to more than one of its ten constituent tumour-associated peptides (TUMAPs), show Phase I and II data reported in Nature Medicine.
You may also be interested in...
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.